الفهرس | Only 14 pages are availabe for public view |
Abstract CSVD is among the neurological diseases known to reduce the quality of life in the elderly. It has a strong role in age-related disabilities such as cognitive impairment, gait apraxia, urinary incontinence, and depression as well as being a leading cause of vascular dementia. Diagnosis of CSVD is based on brain imaging biomarkers, in the form of recent small subcortical infarcts, WMH, lacunes, CMBs, EPVS, and cerebral atrophy. MRI visual rating scales have been used as a tool to diagnose CSVD, and to assess progression and prognosis. Studies have shown that the role of rating scales is better in differential diagnosis rather than lesion progression. There is growing evidence that various subtypes of stroke have very diverse underlying pathophysiologies and respond to treatments in different ways. Significant advancements have been made in the prevention and treatment of atherosclerotic and cardioembolic stroke, but little has been made in the treatment of SVD. The effectiveness of CSVD prevention and treatment is limited by our incomplete understanding of its pathophysiology. Currently, the method of treatment is tailored based on the profile of risk factors, the type and severity of biomarkers, and the severity of clinical consequences. |